(July 27, 2023) – Carbon Medical Technologies, Inc. a Saint Paul based company that designs, develops, and manufacturers pyrolytic carbon-based implantable medical devices is pleased to announce that the United States Patent and Trademark Office has issued a patent (U.S. Pat. No. 11,701,451) for our latest medical device.
The newly patented BiomarC Restore is a pyrolytic carbon coated discrete marker that is embedded into lyophilized glucan as a means of stabilizing the marker within the surgical cavity. The BiomarC Restore lumpectomy cavity fiducial marker is intended to be placed into the body during an open surgical procedure to accurately mark tissue and act as a distinctive reference point during radiation treatment planning helping with challenges faced during breast conserving surgery. Its unique lyophilized glucan matrix allows for tissue in-growth during the healing process.
“We are thrilled to receive a patent for this innovative medical device” said Stephanie Kent, President and Chief Executive Officer at Carbon Medical Technologies, Inc. “This is a major milestone for our company, and it represents our commitment to bring to market safe and effective medical devices that improve the lives of patients.” For more information about our company and our latest medical device, BiomarC Restore, please visit our website at www.carbonmed.com. About Carbon Medical Technologies, Inc. Carbon Medical Technologies, Inc. (CMT) is a privately held company formed in 1994 to design, develop, and manufacture permanent human implantable products utilizing pyrolytic carbon. Carbon is a naturally occurring element in the human body. As a result, pyrolytic carbon is not recognized by the human body as foreign, thus rendering it ideal as a permanent implant material. CMT operates a fully functional pyrolytic carbon coating facility and has developed multiple FDA approved, cleared to market, and CE Marked products. Currently, the pyrolytic carbon coating technology is incorporated into BiomarC implantable tissue markers developed for biopsy site marking, the BiomarC fiducial marker product line for radiation therapy treatment planning, and an injectable bulking agent called Durasphere, which is used for the treatment of stress urinary incontinence in women, and additional indications outside of the US. CMT also provides product development, contract manufacturing, and regulatory consulting for medical device companies. The company is a medical device manufacturer with ISO 13485 certified and cGMP compliant quality systems, maintains three different sterilization method validations, and does final product assembly and packaging in an ISO Class 7 clean room environment.